Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion

Kazunori Toyoda, Kenichiro Fujii, Masahiro Kamouchi, Hiroshi Nakane, Shoji Arihiro, Yasushi Okada, Setsuro Ibayashi, Mitsuo Iida

研究成果: ジャーナルへの寄稿記事

116 引用 (Scopus)

抄録

Background: Edaravone has potent free radical quenching and antioxidant actions. The agent has been recently in commercial use for acute ischemic stroke patients. In this study, we investigated the therapeutic effect of edaravone on severe carotid-territorial stroke. Methods: Stroke patients with internal carotid artery occlusion and baseline NIH Stroke Scale Score ≥15 were treated for 14 days with drip intravenous infusion of edaravone (n=30) and were compared with a historical control cohort of similar patients (n=31). Glycerol was also administered to all patients in both groups. Results: Infarct volume (P<0.02) and midline shift (P<0.02) on CT performed on day 2 of the patients treated with edaravone were smaller than those without edaravone. For patients with edaravone, infarct volume (P<0.0001) and midline shift (P<0.0001) on days 5-7 were greater than those on day 2. Hemorrhagic transformation of infarcts on day 2 was less severe in patients with than without edaravone (P<0.03). Within 14 days after the onset of stroke, 6 patients with edaravone (20%) and 14 without edaravone (45%) died directly of stroke (P<0.03). Among all patients, only two treated with edaravone were independent without any assistance 8 weeks after the onset. Conclusions: Edaravone was associated with delayed evolution of infarcts and edema in patients with severe carotid-territorial stroke and decreased mortality during the acute stage. The agent, however, failed to prevent evolution of infarcts and edema on later days, and did not significantly improve functional outcome among the surviving patients.

元の言語英語
ページ(範囲)11-17
ページ数7
ジャーナルJournal of the Neurological Sciences
221
発行部数1-2
DOI
出版物ステータス出版済み - 6 15 2004

Fingerprint

Free Radical Scavengers
Internal Carotid Artery
Stroke
Intravenous Infusions
Edema
phenylmethylpyrazolone
Therapeutic Uses
Glycerol
Free Radicals
Antioxidants

All Science Journal Classification (ASJC) codes

  • Neurology
  • Clinical Neurology

これを引用

Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. / Toyoda, Kazunori; Fujii, Kenichiro; Kamouchi, Masahiro; Nakane, Hiroshi; Arihiro, Shoji; Okada, Yasushi; Ibayashi, Setsuro; Iida, Mitsuo.

:: Journal of the Neurological Sciences, 巻 221, 番号 1-2, 15.06.2004, p. 11-17.

研究成果: ジャーナルへの寄稿記事

Toyoda, K, Fujii, K, Kamouchi, M, Nakane, H, Arihiro, S, Okada, Y, Ibayashi, S & Iida, M 2004, 'Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion', Journal of the Neurological Sciences, 巻. 221, 番号 1-2, pp. 11-17. https://doi.org/10.1016/j.jns.2004.03.002
Toyoda, Kazunori ; Fujii, Kenichiro ; Kamouchi, Masahiro ; Nakane, Hiroshi ; Arihiro, Shoji ; Okada, Yasushi ; Ibayashi, Setsuro ; Iida, Mitsuo. / Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion. :: Journal of the Neurological Sciences. 2004 ; 巻 221, 番号 1-2. pp. 11-17.
@article{a1b74a0b59a441ac90ddf11ef35b1a18,
title = "Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion",
abstract = "Background: Edaravone has potent free radical quenching and antioxidant actions. The agent has been recently in commercial use for acute ischemic stroke patients. In this study, we investigated the therapeutic effect of edaravone on severe carotid-territorial stroke. Methods: Stroke patients with internal carotid artery occlusion and baseline NIH Stroke Scale Score ≥15 were treated for 14 days with drip intravenous infusion of edaravone (n=30) and were compared with a historical control cohort of similar patients (n=31). Glycerol was also administered to all patients in both groups. Results: Infarct volume (P<0.02) and midline shift (P<0.02) on CT performed on day 2 of the patients treated with edaravone were smaller than those without edaravone. For patients with edaravone, infarct volume (P<0.0001) and midline shift (P<0.0001) on days 5-7 were greater than those on day 2. Hemorrhagic transformation of infarcts on day 2 was less severe in patients with than without edaravone (P<0.03). Within 14 days after the onset of stroke, 6 patients with edaravone (20{\%}) and 14 without edaravone (45{\%}) died directly of stroke (P<0.03). Among all patients, only two treated with edaravone were independent without any assistance 8 weeks after the onset. Conclusions: Edaravone was associated with delayed evolution of infarcts and edema in patients with severe carotid-territorial stroke and decreased mortality during the acute stage. The agent, however, failed to prevent evolution of infarcts and edema on later days, and did not significantly improve functional outcome among the surviving patients.",
author = "Kazunori Toyoda and Kenichiro Fujii and Masahiro Kamouchi and Hiroshi Nakane and Shoji Arihiro and Yasushi Okada and Setsuro Ibayashi and Mitsuo Iida",
year = "2004",
month = "6",
day = "15",
doi = "10.1016/j.jns.2004.03.002",
language = "English",
volume = "221",
pages = "11--17",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Free radical scavenger, edaravone, in stroke with internal carotid artery occlusion

AU - Toyoda, Kazunori

AU - Fujii, Kenichiro

AU - Kamouchi, Masahiro

AU - Nakane, Hiroshi

AU - Arihiro, Shoji

AU - Okada, Yasushi

AU - Ibayashi, Setsuro

AU - Iida, Mitsuo

PY - 2004/6/15

Y1 - 2004/6/15

N2 - Background: Edaravone has potent free radical quenching and antioxidant actions. The agent has been recently in commercial use for acute ischemic stroke patients. In this study, we investigated the therapeutic effect of edaravone on severe carotid-territorial stroke. Methods: Stroke patients with internal carotid artery occlusion and baseline NIH Stroke Scale Score ≥15 were treated for 14 days with drip intravenous infusion of edaravone (n=30) and were compared with a historical control cohort of similar patients (n=31). Glycerol was also administered to all patients in both groups. Results: Infarct volume (P<0.02) and midline shift (P<0.02) on CT performed on day 2 of the patients treated with edaravone were smaller than those without edaravone. For patients with edaravone, infarct volume (P<0.0001) and midline shift (P<0.0001) on days 5-7 were greater than those on day 2. Hemorrhagic transformation of infarcts on day 2 was less severe in patients with than without edaravone (P<0.03). Within 14 days after the onset of stroke, 6 patients with edaravone (20%) and 14 without edaravone (45%) died directly of stroke (P<0.03). Among all patients, only two treated with edaravone were independent without any assistance 8 weeks after the onset. Conclusions: Edaravone was associated with delayed evolution of infarcts and edema in patients with severe carotid-territorial stroke and decreased mortality during the acute stage. The agent, however, failed to prevent evolution of infarcts and edema on later days, and did not significantly improve functional outcome among the surviving patients.

AB - Background: Edaravone has potent free radical quenching and antioxidant actions. The agent has been recently in commercial use for acute ischemic stroke patients. In this study, we investigated the therapeutic effect of edaravone on severe carotid-territorial stroke. Methods: Stroke patients with internal carotid artery occlusion and baseline NIH Stroke Scale Score ≥15 were treated for 14 days with drip intravenous infusion of edaravone (n=30) and were compared with a historical control cohort of similar patients (n=31). Glycerol was also administered to all patients in both groups. Results: Infarct volume (P<0.02) and midline shift (P<0.02) on CT performed on day 2 of the patients treated with edaravone were smaller than those without edaravone. For patients with edaravone, infarct volume (P<0.0001) and midline shift (P<0.0001) on days 5-7 were greater than those on day 2. Hemorrhagic transformation of infarcts on day 2 was less severe in patients with than without edaravone (P<0.03). Within 14 days after the onset of stroke, 6 patients with edaravone (20%) and 14 without edaravone (45%) died directly of stroke (P<0.03). Among all patients, only two treated with edaravone were independent without any assistance 8 weeks after the onset. Conclusions: Edaravone was associated with delayed evolution of infarcts and edema in patients with severe carotid-territorial stroke and decreased mortality during the acute stage. The agent, however, failed to prevent evolution of infarcts and edema on later days, and did not significantly improve functional outcome among the surviving patients.

UR - http://www.scopus.com/inward/record.url?scp=2642551352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2642551352&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2004.03.002

DO - 10.1016/j.jns.2004.03.002

M3 - Article

C2 - 15178207

AN - SCOPUS:2642551352

VL - 221

SP - 11

EP - 17

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -